G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 28.05 SEK 3.13% Market Closed
Market Cap: 1.8B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genovis AB
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
G
Genovis AB
STO:GENO
Operating Income
kr23.2m
CAGR 3-Years
41%
CAGR 5-Years
31%
CAGR 10-Years
N/A
AddLife AB
STO:ALIF B
Operating Income
kr805m
CAGR 3-Years
5%
CAGR 5-Years
36%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Operating Income
-kr100m
CAGR 3-Years
-24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Operating Income
kr351m
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
22%
MedCap AB (publ)
STO:MCAP
Operating Income
kr294.3m
CAGR 3-Years
38%
CAGR 5-Years
33%
CAGR 10-Years
32%
M
Magle Chemoswed Holding AB
STO:MAGLE
Operating Income
kr21.7m
CAGR 3-Years
69%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Genovis AB
Glance View

Market Cap
1.8B SEK
Industry
Life Sciences Tools & Services

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

GENO Intrinsic Value
24.64 SEK
Overvaluation 12%
Intrinsic Value
Price
G

See Also

What is Genovis AB's Operating Income?
Operating Income
23.2m SEK

Based on the financial report for Jun 30, 2024, Genovis AB's Operating Income amounts to 23.2m SEK.

What is Genovis AB's Operating Income growth rate?
Operating Income CAGR 5Y
31%

Over the last year, the Operating Income growth was -51%. The average annual Operating Income growth rates for Genovis AB have been 41% over the past three years , 31% over the past five years .

Back to Top